

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Attorney Docket No.: 02-456-A1)

In re Application of:	)	
	)	
Varghese John	)	Examiner: Sahar Javanmard
	)	
Serial No.: 10/519,793	)	
	)	Art Unit: 1617
Filed: August 25, 2005	)	
	)	Confirmation No.: 3057
For: Methods for Treating	)	
Alzheimer's Disease Using	)	
Hydroxyethylene Compounds	)	
Containing a Heterocyclic Amide	)	
Bond Isostere	)	

**RESPONSE TO THE RESTRICTION REQUIREMENT**  
**MAILED NOVEMBER 28, 2007**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


Responsive to the Restriction Requirement mailed November 28, 2007, the Applicants elect the claims of Group I, i.e., claims 1-6 and 20, for prosecution.

To comply with the requirement for species elections, the Applicants further elect as follows:

with respect to a disease from the list in claim 5: Alzheimer's disease; and

with respect to a compound: benzyl (S)-1-((2S,3S,5R)-3-hydroxy-5-(5-isobutyryl-1H-imidazol-2-yl)-1,6-diphenylhexan-2-ylamino)-3-methyl-1-oxobutan-2-ylcarbamate.

The above-identified compound species is the first compound listed in claim 6 and can be represented by the following structural formula:



The claims that read on the species of Alzheimer's disease are claims 1-6 and 20.

The claims that read on the compound species identified above are claims 1-6 and 20.

The Applicants invite the Examiner to contact the Applicants' undersigned representative at (312) 913-2136 if the Examiner believes that this would expedite prosecution of this application.

December 20, 2007

Respectfully submitted,  
By: /Steven J. Sarussi/  
Steven J. Sarussi  
Reg. No. 32784

McDonnell Boehnen  
Hulbert & Berghoff LLP  
300 S. Wacker Drive  
Chicago, IL 60606  
(312) 913-2136